Short Interest Update on Nektar Therapeutics (NKTR)

Nektar Therapeutics (NKTR) : 9 days before expiry, shorts in Nektar Therapeutics (NKTR) have reduced from 10,356,276 on Jul 29, 2016, to 9,631,313 on August 15, 2016. On an average, 1,044,387 shares are traded on the exchange. The outstanding bearish positions are equal to 7.1% of the float. Short sellers have covered -724,963 shares, a reduction of -7%, which underlines that they dont expect the stock to fall further from the current levels. The short interest information was released on Wednesday Aug 24th after the market close.

Nektar Therapeutics (NASDAQ:NKTR): The stock opened at $18.17 on Wednesday but the bulls could not build on the opening and the stock topped out at $18.70 for the day. The stock traded down to $17.44 during the day, due to lack of any buying support eventually closed down at $17.58 with a loss of -3.19% for the day. The stock had closed at $18.16 on the previous day. The total traded volume was 1,037,080 shares.


In a related news,The officer (SVP & Chief Operating Officer) of Nektar Therapeutics, Nicholson John sold 3,317 shares at $17.56 on August 16, 2016. The Insider selling transaction had a total value worth of $58,247. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.

Nektar Therapeutics is a clinical-stage biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. The Companys pipeline is comprised of drug candidates for therapeutic areas, including oncology, pain, anti-infectives, and immunology. The Companys research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates. Its drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient. Its polymer chemistry platform is being used to create specialized therapeutics, including small molecule oral and parenteral drugs, proteins, peptides and antibody fragments.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.